Security agreement

Great Elm Capital Corp. Announces Public Offering of Unsecured Notes

Retrieved on: 
Monday, August 7, 2023
Note, Oppenheimer, Security agreement, Sale, Prospectus, City National Bank, Loan, Security (finance)

WALTHAM, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC) announced today the commencement of an underwritten public offering of unsecured notes due 2028 (the “Notes”).

Key Points: 
  • WALTHAM, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC) announced today the commencement of an underwritten public offering of unsecured notes due 2028 (the “Notes”).
  • The Notes are expected to be listed on The Nasdaq Global Market under the trading symbol “GECCZ,” and to trade thereon within 30 days from the original issue date.
  • The interest rate and other terms of the Notes will be determined by negotiations between the Company and the underwriters.
  • Ladenburg Thalmann & Co. Inc., Janney Montgomery Scott LLC and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.

Columbus McKinnon Successfully Completes Planned Refinancing

Retrieved on: 
Monday, June 26, 2023
Technology, Defense, Other Energy, Other Defense, Coal, Energy, Automotive, Building Systems, Trucking, Rail, Transport, Other Manufacturing, Other Technology, General Automotive, Other Construction & Property, Engineering, Commercial Building & Real Estate, Chemicals, Plastics, Construction & Property, Automotive Manufacturing, Electronic Design Automation, Logistics, Supply Chain Management, Manufacturing, Borrowing base, Credit agreements in South Africa, SOFR, Security agreement, Gesellschaft mit beschränkter Haftung, Security, Motion, Acquisition, CMCO, Growth, Credit, Bank

Columbus McKinnon Corporation (Nasdaq: CMCO), a leading designer and manufacturer of intelligent motion solutions for material handling, today announced that it amended and expanded its Credit Agreement to increase its Term Loan B borrowings by an additional $75 million under the agreement (“Incremental Term Loan B”).

Key Points: 
  • Columbus McKinnon Corporation (Nasdaq: CMCO), a leading designer and manufacturer of intelligent motion solutions for material handling, today announced that it amended and expanded its Credit Agreement to increase its Term Loan B borrowings by an additional $75 million under the agreement (“Incremental Term Loan B”).
  • Following the amendment, total borrowings under the Term Loan B, which matures in May 2028, are approximately $537.6 million.
  • We have a strong cash generating business, are highly disciplined in our capital allocation and carefully manage our capital structure.
  • We believe our financial strategy is integral to our strategy to transform Columbus McKinnon into a higher growth, less cyclical business with stronger earnings power and a leader in intelligent motion solutions for material handling.”

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 22, 2023
Interim, Hepatocellular carcinoma, Cancer, Security agreement, Research, RNA, Lung cancer, PwC, Eli Lilly, Genzyme, Acquisition, Investment, Patient, Melanoma, FDA, Loan, Market for corporate control, Renal cell carcinoma, Pharmaceutical industry, Vaccine, Cryptocurrency, IND

On May 9, 2023, Oncorus appointed Alexander Nolte as its interim Chief Financial Officer.

Key Points: 
  • On May 9, 2023, Oncorus appointed Alexander Nolte as its interim Chief Financial Officer.
  • Research and development expenses for the quarter ended March 31, 2023 were $10.6 million compared to $12.5 million for the corresponding quarter in 2022.
  • General and administrative expenses for the quarter ended March 31, 2023 were $4.5 million compared to $5.3 million for the corresponding quarter in 2022.
  • Oncorus expects its cash, cash equivalents and investments, following the full prepayment of its debt capital facility with K2HV in May 2023, to fund its operations into the third quarter of 2023.

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, May 12, 2023
CLL, Waldenström macroglobulinemia, Mayo Clinic, Arm, Chronic lymphocytic leukemia, Follicular lymphoma, Fred Hutchinson Cancer Research Center, ICML, Clinical trial, Lymphoma, Security agreement, Research, Runway, Translation, WM, Waldenström, CAR, Hematological Cancer Research Investment and Education Act, International Conference on Afghanistan, London (2010), Patient, Clinical professor, FDA, Loan, Mustang, Conference, DSM-IV codes, Safety, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.
  • The final dose level escalation is anticipated in the Phase 1 indolent lymphoma arm in the third quarter of this year.
  • Research and development expenses were $14.0 million for the first quarter of 2023, compared to $16.3 million for the first quarter of 2022.
  • General and administrative expenses were $2.3 million for the first quarter of 2023, compared to $3.3 million for the first quarter of 2022.

MicroStrategy Announces First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 1, 2023
Technology, Fintech, Business, Professional Services, Digital Cash Management, Digital Assets, Software, Data Analytics, Cryptocurrency, Data Management, Cash, Additional funds needed, Table, MSTR, GAAP, Security agreement, Sale, Judgement, Acquisition, Digital asset, Purchase and sale agreement, Digital, Growth, Credit, Silvergate, MicroStrategy, Silvergate Bank, Video game, Security (finance), Bank

MicroStrategy® Incorporated (Nasdaq: MSTR) (“MicroStrategy” or the “Company”), the largest independent publicly-traded business intelligence company, today announced financial results for the three-month period ended March 31, 2023 (the first quarter of its 2023 fiscal year).

Key Points: 
  • MicroStrategy® Incorporated (Nasdaq: MSTR) (“MicroStrategy” or the “Company”), the largest independent publicly-traded business intelligence company, today announced financial results for the three-month period ended March 31, 2023 (the first quarter of its 2023 fiscal year).
  • Operating Expenses: Operating expenses for the first quarter of 2023 were $114.3 million, a 56.6% decrease compared to the first quarter of 2022.
  • MicroStrategy believes the use of these non-GAAP financial measures can also facilitate comparison of MicroStrategy’s operating results to those of its competitors.
  • MicroStrategy will be discussing its first quarter 2023 financial results on a live Video Webinar today beginning at approximately 5:00 p.m.

Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update

Retrieved on: 
Thursday, March 30, 2023
PD, Orange County Convention Center, Neoplasm, RECIST, Section 13, Capillary leak syndrome, Patient, Investment, Therapy, Immunogenic cell death, TD, Symantec Endpoint Protection, Security agreement, Lung cancer, CD8, HIV disease progression rates, Bristol Myers Squibb, TME, ETB 4, IND, PD-L1, Conference, Safety, CD38, HLA, HER2, Aes, MHC, Cancer, American Association for Cancer Research, NSCLC, Immunoglobulin A, Antibody, CMV, Webcast, ETB, Pembrolizumab, Workforce, Genotype, Immunomodulatory imide drug, Security, Toxic epidermal necrolysis, Tumor microenvironment, BCMA, Pharmaceutical industry, Medical imaging, Palladium, Cement, Vaccine, Mineral wool, Breast

Revenues for the fourth quarter of 2022 were $2.6 million, compared to $18.0 million for the same period in 2021.

Key Points: 
  • Revenues for the fourth quarter of 2022 were $2.6 million, compared to $18.0 million for the same period in 2021.
  • Revenues for the fourth quarter of 2022 were comprised of revenues from collaborative research and development agreements with Bristol Myers Squibb.
  • Total research and development expenses for the fourth quarter of 2022 were $17.6 million, compared with $19.3 million for the same period in 2021.
  • Total general and administrative expenses for the fourth quarter of 2022 were $6.1 million, compared with $7.9 million for the same period in 2021.

Direct Digital Holdings Reports Fourth Quarter & Full-Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
Advertising, Failure, DRCT, Marketing, Result, Risk, Line of credit, Disclosure, Computer, Tax, Conversation, GAAP, Security agreement, Ratio, Primary Dealer Credit Facility, Security, Silicon, EBITDA, Analysis, Direct digital marketing, Colossus, Webcast, IDS, Growth, Financial condition report, Security (finance), Loan, Credit, Software, Online shopping, Video game, Music, Cryptocurrency, Tobacco, Bank

HOUSTON, March 23, 2023 /PRNewswire/ -- Direct Digital Holdings, Inc. (Nasdaq: DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP"), Huddled Masses LLC ("Huddled Masses") and Orange142, LLC ("Orange142"), today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.

Key Points: 
  • HOUSTON, March 23, 2023 /PRNewswire/ -- Direct Digital Holdings, Inc. (Nasdaq: DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP"), Huddled Masses LLC ("Huddled Masses") and Orange142, LLC ("Orange142"), today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.
  • Fourth Quarter 2022 Financial Highlights:
    Revenue was $29.4 million in the fourth quarter of 2022, an increase of $16.5 million, or 128% over the $12.9 million in the same period of 2021.
  • Adjusted EBITDA(1) was $1.8 million in the fourth quarter 2022, compared to $1.8 million in the same period of 2021.
  • Direct Digital will host a conference call on Thursday, March 23, 2023 at 5:00 p.m. Eastern Time to discuss the Company's fourth quarter and full-year financial results.

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, Mutation, Table, Sale, Oxford, Institute of Cancer Research, Research and development, KRAS, Shijiazhuang Pharma Group, Medicine, FRAME, Avutometinib, Term, Security agreement, Strategic management, RAMP, Royal Marsden Hospital, Patient, General Administration of Press and Publication, Investment, Bank statement, Food and Drug Administration, Research, The Institute, FDA, GAAP, Disease, NSCLC, RAS, ORR, Geron Corporation, Patent, Food, Intellectual property, The Royal Marsden NHS Foundation Trust, Pharmaceutical industry, Vaccine, Security (finance), Cryptocurrency, Video game, Bank, Verastem Oncology, SECURA Insurance

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.
  • Verastem Oncology ended the fourth quarter of 2022 with cash, cash equivalents and investments of $87.9 million.
  • Research & development expenses for the 2022 Quarter were $10.7 million, compared to $11.4 million for the 2021 Quarter.
  • Selling, general & administrative expenses for the 2022 Quarter were $6.1 million, compared to $5.7 million for the 2021 Quarter.

Vapotherm Announces Amendment to Debt Agreement

Retrieved on: 
Tuesday, November 22, 2022
General Health, Health, Other Health, Medical Devices, Asset-backed security, SLR, Failure, PIK, Strike, Food and Drug Administration Amendments Act of 2007, Gas, VAPO, Patent, Adjustment, Thirty-third Amendment of the Constitution of Ireland, NYSE, Food, Finance Secretary (India), Security agreement, Security (finance), Breathe Me, Food and Drug Administration, Second Amendment to the United States Constitution, Hypoxemia, Term, Growth, LIBOR, COVID-19, Loan, Regulation, Regulation Fair Disclosure, Amendment, Security, Patient, Vapotherm

3 to its Loan and Security Agreement (the Third Amendment, with SLR Investment Corp. (SLR), as Collateral Agent, and the lenders party thereto.

Key Points: 
  • 3 to its Loan and Security Agreement (the Third Amendment, with SLR Investment Corp. (SLR), as Collateral Agent, and the lenders party thereto.
  • The Loan and Security Agreement matures on February 1, 2027 (the Maturity Date).
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.